Table 1

Description of HRT Trials.

Study

Length months

Type of Oestrogen

Progestin+ Addition of calcium^*

Study Population

Outcome measure

Age (SD/range)

Alexandersen 1999 [12]

22

50-ug transdermal estradiol

+^*

Healthy postmenopausal women with low BMD

BMD

65 (2.2)

Delmas 2000 [5]

24

Oral 1 mg estradiol

+^*

Healthy >1 year postmenopausal women with normal BMD.

BMD

58 (5)

Gallagher 2001 [14]

36

Oral 0.625 mg conjugated estrogens

+^*

Elderly women with normal bone density

BMD

72(± 4)

Cauley 2001 [4]

49

Oral 0.625 conjugated estrogen

+

Women with established coronary disease >5 years post menopause

MI or CHD

67

Herrington 2000 [6]

38

Oral 0.625 conjugated estrogen

+

Women with coronary arterial disease (CAD)

CAD Progression

66 (7.0)

Ishida 2001 [15]

12

Oral 0.625 conjugated estrogen.

+

Women with established osteoporosis.

BMD

70 (7.6)

Lindsay 1990 [13]

24

Oral 0.625 mg conjugated estrogen

+^*

Postmenopausal women with 1+ vertebral fracture & low BMD

BMD

48 (1.0)

Lufkin 1992 [1]

12

Transdermal 0.1 mg 17β-estradiol

+

Postmenopausal white women with documented osteoporosis

BMD

64.8 (54.9 to 71.3)

Mosekilde 2000 [7]

60

Oral 1 mg or 2 mg estradiol

+

Healthy women 3–24 months post menopause

Fractures

50 (2.8)

PEPI 1996 [8]

36

Oral 0.625 mg conjugated estrogen

+

Healthy women 1–10 years post menopause normal BMD

BMD

56 (0.3)

Ravn 1999 [9]

48

Oral 0.625 conjugated estrogen or 2 mg estradiol

+

Healthy 6+ months postmenopausal women under 60 years

BMD

55

Recker 1999 [10]

42

0.3 mg conjugated estrogen

+^*

Healthy women average BMD t-score-3.5 at femur

BMD

73 (5.0)

Wimalawansa 1998 [11]

48

Oral 0.625 conjugated estrogen

+^*

Women with established osteoporosis (1+vertebral fracture)

BMD

65 (0.9)

Torgerson and Bell-Syer BMC Musculoskeletal Disorders 2001 2:7   doi:10.1186/1471-2474-2-7